AI English summary of an SEC filing — figures as filed
Edwards Lifesciences EWThe company said net sales for Q3 2025 were $1,553.1 million, up 14.7% from $1,354.4 million in the prior year, with adjusted growth of 12.6%.
Key points
AI summaryThe company said net sales for Q3 2025 were $1,553.1 million, up 14.7% from $1,354.4 million in the prior year, with adjusted growth of 12.6%.
The company said TAVR sales for Q3 were $1.15 billion, up 12.4% on a constant currency basis of 10.6%, and TMTT sales were $145.2 million, up 59.3%. It said TMTT growth was driven by PASCAL and EVOQUE.
The company said net income from continuing operations for Q3 was $292.3 million with diluted EPS of $0.50, and adjusted diluted EPS excluding litigation expenses of $90.4 million was $0.67. Operating profit margin was 19.8% on a GAAP basis and 27.5% as adjusted.
The company said it raised its full-year 2025 adjusted EPS guidance to $2.56 to $2.62 from the high end of $2.45 to $2.55, and increased its TAVR sales growth guidance to 7 to 8% from 6 to 7%. It projected Q4 sales of $1.51 to $1.59 billion.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 Net Sales $1.55 billion, Up 12.6% on Adjusted Basis
The company said net sales for Q3 2025 were $1,553.1 million, up 14.7% from $1,354.4 million in the prior year, with adjusted growth of 12.6%.
Source · Based on the filing body and exhibits
TAVR Q3 Sales $1.15 billion, TMTT $145.2 million
The company said TAVR sales for Q3 were $1.15 billion, up 12.4% on a constant currency basis of 10.6%, and TMTT sales were $145.2 million, up 59.3%. It said TMTT growth was driven by PASCAL and EVOQUE.
Source · Based on the filing body and exhibits
Q3 GAAP Net Income $292.3 million, Adjusted EPS $0.67
The company said net income from continuing operations for Q3 was $292.3 million with diluted EPS of $0.50, and adjusted diluted EPS excluding litigation expenses of $90.4 million was $0.67. Operating profit margin was 19.8% on a GAAP basis and 27.5% as adjusted.
Source · Based on the filing body and exhibits
Full-Year Guidance Raised: Adjusted EPS $2.56 to $2.62
The company said it raised its full-year 2025 adjusted EPS guidance to $2.56 to $2.62 from the high end of $2.45 to $2.55, and increased its TAVR sales growth guidance to 7 to 8% from 6 to 7%. It projected Q4 sales of $1.51 to $1.59 billion.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…